Bide Pharmatech Co. Ltd. Class A

As of June 30, 2026, Bide Pharmatech Co. Ltd. Class A carries a market capitalization of 4.89B, placing it among publicly traded companies globally. Its enterprise value stands at 4.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bide Pharmatech Co. Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Bide Pharmatech Co. Ltd. Class A has 90.88M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Bide Pharmatech Co. Ltd. Class A maintains a current ratio of 7.46, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Bide Pharmatech Co. Ltd. Class A recorded 37.51M in income tax expense.

As of the close on October 22, 2026, Bide Pharmatech Co. Ltd. Class A's stock has declined approximately 14.77% over the past 52 weeks. The 50-day moving average sits at 67.13, while the 200-day moving average is 59.48.

As of June 30, 2026, Bide Pharmatech Co. Ltd. Class A holds 1.02B in cash and equivalents against 136.91M in total debt, resulting in a net debt position of -756.36M. Total book value stands at 2.06B, with working capital of 1.99B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Bide Pharmatech Co. Ltd. Class A paid dividends of 1.18 per share.

Bide Pharmatech Co. Ltd. Class A's most recent stock split took place on May 25, 2023 with a 5:7 split ratio.